Original Research

HbA_1c Change in Patients With and Without Gaps in Pharmacist Visits at a Safety-Net Resident Physician Primary Care Clinic

Journal of Clinical Outcomes Management. 2021 May;28(3):112-121 | 10.12788/jcom.0046

References

1. Manolakis PG, Skelton JB. Pharmacists’ contributions to primary care in the United States collaborating to address unmet patient care needs: the emerging role for pharmacists to address the shortage of primary care providers. Am J Pharm Educ. 2010;74(10):S7.

2. Scott MA, Hitch B, Ray L, Colvin G. Integration of pharmacists into a patient-centered medical home. J Am Pharm Assoc (2003). 2011;51(2):161‐166.

3. Wong SL, Barner JC, Sucic K, et al. Integration of pharmacists into patient-centered medical homes in federally qualified health centers in Texas. J Am Pharm Assoc (2003). 2017;57(3):375‐381.

4. Sapp ECH, Francis SM, Hincapie AL. Implementation of pharmacist-driven comprehensive medication management as part of an interdisciplinary team in primary care physicians’ offices. Am J Accountable Care. 2020;8(1):8-11.

5. Cowart K, Olson K. Impact of pharmacist care provision in value-based care settings: How are we measuring value-added services? J Am Pharm Assoc (2003). 2019;59(1):125-128.

6. Centers for Disease Control and Prevention. Pharmacy: Collaborative Practice Agreements to Enable Drug Therapy Management. January 16, 2018. Accessed April 17, 2021. https://www.cdc.gov/dhdsp/pubs/guides/best-practices/pharmacist-cdtm.htm

7. Choe HM, Farris KB, Stevenson JG, et al. Patient-centered medical home: developing, expanding, and sustaining a role for pharmacists. Am J Health Syst Pharm. 2012;69(12):1063-1071.

8. Coe AB, Choe HM. Pharmacists supporting population health in patient-centered medical homes. Am J Health Syst Pharm. 2017;74(18):1461-1466.

9. Luder HR, Shannon P, Kirby J, Frede SM. Community pharmacist collaboration with a patient-centered medical home: establishment of a patient-centered medical neighborhood and payment model. J Am Pharm Assoc (2003). 2018;58(1):44-50.

10. Matzke GR, Moczygemba LR, Williams KJ, et al. Impact of a pharmacist–physician collaborative care model on patient outcomes and health services utilization. 10.05Am J Health Syst Pharm. 2018;75(14):1039-1047.

11. Aneese NJ, Halalau A, Muench S, et al. Impact of a pharmacist-managed diabetes clinic on quality measures. Am J Manag Care. 2018;24(4 Spec No.):SP116-SP119.

12. Prudencio J, Cutler T, Roberts S, et al. The effect of clinical 10.05pharmacist-led comprehensive medication management on chronic disease state goal attainment in a patient-centered medical home. J Manag Care Spec Pharm. 2018;24(5):423-429.

13. Edwards HD, Webb RD, Scheid DC, et al. A pharmacist visit improves diabetes standards in a patient-centered medical home (PCMH). Am J Med Qual. 2012;27(6) 529-534.

14. Ullah S, Rajan S, Liu T, et al. Why do patients miss their appointments at primary care clinics? J Fam Med Dis Prev. 2018;4:090.

15. Moore CG, Wilson-Witherspoon P, Probst JC. Time and money: effects of no-shows at a family practice residency clinic. Fam Med. 2001;33(7):522-527.

16. Kheirkhah P, Feng Q, Travis LM, et al. Prevalence, predictors and economic consequences of no-shows. BMC Health Serv Res. 2016;16:13.

17. Little RR, Rohlfing C. The long and winding road to optimal HbA10.05_1c10.05 measurement. Clin Chim Acta. 2013;418:63-71.

18. Hill J, Nielsen M, Fox MH. Understanding the social factors that contribute to diabetes: a means to informing health care and social policies for the chronically ill. Perm J. 2013;17(2):67-72.

19. Gonzalez-Zacarias AA, Mavarez-Martinez A, Arias-Morales CE, et al. Impact of demographic, socioeconomic, and psychological factors on glycemic self-management in adults with type 2 diabetes mellitus. Front Public Health. 2016;4:195.

20. Pantalone KM, Misra-Hebert AD, Hobbs TD, et al. The probability of A1c goal attainment in patients with uncontrolled type 2 diabetes in a large integrated delivery system: a prediction model. Diabetes Care. 2020;43:1910-1919.

Another notable finding from this study was that although the average number of pharmacist visits per patient was significantly different, this difference of 1 visit did not result in a statistically significant improvement in HbA_1c. In fact, the average number of pharmacist visits per patient seemed to be within the reported range by Choe et al in a similar setting.⁷ Conversely, patients with a history of a gap in pharmacist visits spent longer durations under pharmacist care compared to those who had continuous follow-up. This could mean that it may take longer times or 1 additional visit to achieve similar HbA_1c results with continuous pharmacist care. Higher number of visits with pharmacists in the group with the history of gaps between pharmacist visits could have been facilitated by resident physicians, as both groups had a similar number of visits with them. Although this is not conclusive, identifying the optimal number of visits with pharmacists in this underserved population could be beneficial in strategizing pharmacist visits. Acute care utilization was not different between the 2 groups, and most cases that led to acute care utilization were not directly related to diabetes or its complications.

The average HbA_1c at the end of the study did not measure < 8%, a target that was reached by less than half of patients from each group; however, this study is a snapshot of a series of ongoing clinical pharmacy services. About 25% of our patients started their first visit with a pharmacist less than 6 months from the study end date, and these patients may not have had enough time with pharmacists for their HbA_1c to reach below the target goal. In addition, most patients in this clinic were enrolled in public health plans and may carry a significant burden of social and behavioral factors that can affect diabetes management.^18,19 These patients may need longer care by pharmacists along with other integrated services, such as behavioral health and social work, to achieve optimal HbA_1c levels.²⁰

There are several limitations to this study, including the lack of a propensity matched control group of patients who only had resident physician visits; thus, it is hard to test the true impact of continuous or intermittent pharmacist visits on the therapeutic outcomes. The study also does not address potential social, economic, and physical environment factors that might have contributed to pharmacist visits and to overall diabetes care. These factors can negatively impact diabetes control and addressing them could help with an individualized diabetes management approach.^17,18 Additionally, by nature of being a descriptive study, the results may be subject to undetermined confounding factors.

Conclusion

Patients maintaining continuous pharmacist visits do not have statistically significant differences in change in HbA_1c compared to patients who had a history of 3-month or longer gaps in pharmacist visits at a resident physician primary care safety-net clinic. However, patients with diabetes will likely derive a benefit in HbA_1c reduction regardless of regularity of pharmacist care. This finding still holds true in collaboration with resident physicians who also regularly meet with patients.

The study highlights that it is important to integrate clinical pharmacists into primary care teams for improved therapeutic outcomes. It is our hope that regular visits to pharmacists can be a gateway for behavioral health and social work referrals, thereby addressing pharmacist-identified social barriers. Furthermore, exploration of socioeconomic and behavioral barriers to pharmacist visits is necessary to address and improve the patient experience, health care delivery, and health outcomes.

Acknowledgments: The authors thank Roxanna Perez, PharmD, Amy Li, and Julie Dopheide, PharmD, BCPP, FASHP for their contributions to this project.

Corresponding author: Michelle Koun Lee Chu, PharmD, BCACP, APh, Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, 1985 Zonal Ave, Los Angeles, CA 90089-9121; lee118@usc.edu.

Financial disclosures: None.